Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ)
Tianjin, CN
Tianjin Lisheng Pharmaceutical Co.,Ltd. specializes in the manufacturing and distribution of chemical pharmaceutical products. Their extensive catalog features a variety of finished dosage forms, including tablets, hard capsules, dripping pills, freeze-dried powder injections, and water injections, alongside bulk medicines. The company also provides pharmaceutical intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. Headquartered in Tianjin, China, the firm extends its reach through product exports. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.36% | -1.59% | -11.60% | -18.17% | -13.50% | -17.86% | -8.38% | +0.20% | +27.34% | -25.85% | -57.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.2% Q1'26: -10.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+125.0% ★ Q1'26: -4.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+38.5% ★ Q1'26: -0.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+32.8% ★ Q1'26: +18.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+18.6% ★ Q1'26: +9.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.8% Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.33× ★ Q1'26: 0.17× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
763.64M
est: 744.79M (+2.5%)
|
1.12B
est: 888.60M (+25.7%)
|
1.39B
est: 1.48B (-5.6%)
|
1.67B
1.67B – 1.67B
+12.9% YoY
|
1.94B
1.94B – 1.94B
+16.5% YoY
|
| EBITDA |
406.12M
est: 155.72M (+160.8%)
|
388.14M
est: 185.79M (+108.9%)
|
533.40M
est: 403.77M (+32.1%)
|
455.78M
455.78M – 455.78M
+12.9% YoY
|
530.79M
530.79M – 530.79M
+16.5% YoY
|
| EBIT |
409.44M
est: 112.88M (+262.7%)
|
363.13M
est: 134.68M (+169.6%)
|
456.43M
est: 320.69M (+42.3%)
|
362.00M
362.00M – 362.00M
+12.9% YoY
|
421.57M
421.57M – 421.57M
+16.5% YoY
|
| Net Income |
324.77M
|
297.11M
|
418.37M
est: 342.18M (+22.3%)
|
344.33M
344.33M – 344.33M
+0.6% YoY
|
348.64M
348.64M – 348.64M
+1.3% YoY
|
| SGA |
137.49M
est: 234.11M (-41.3%)
|
345.86M
est: 279.31M (+23.8%)
|
302.50M
est: 523.15M (-42.2%)
|
590.54M
590.54M – 590.54M
+12.9% YoY
|
687.72M
687.72M – 687.72M
+16.5% YoY
|
| EPS |
1.90
|
1.63
|
1.62
est: 1.33 (+22.3%)
|
1.33
1.33 – 1.33
+0.6% YoY
|
1.35
1.35 – 1.35
+1.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-25 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 151.0K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.9K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 11.1K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 547.3K | 0.06% |
| 5 | Vanguard Total International Stock ETF VXUS | 0.00% | 485.4K | 0.05% |
| 6 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 879.52 | 0.22% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.6K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.4K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 627.50 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 72.51 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changfeng Long | Chief Engineer & Deputy GM | — | male |
| Feifei Ma | Secretary of the Board | — | female |
| Fujun Wang | GM & Non-Independent Director | — | male |
| Gao Jun | Accounting Supervisor | — | — |
| Jiankang Liang | Deputy General Manager | — | male |
| Jiaying Wang | Financial Director | — | male |
| Xiaoyan Guo | Deputy General Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002393.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
